SCHEMBL19865535

SCHEMBL19865535

CN(CO)CCN(C)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.35
HDAC6 Q9UBN7 2/20 0.34
CA14 Q9ULX7 2/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
PDK2 Q15119 1/20 0.34
CTSL P07711 2/20 0.32
CTSB P07858 2/20 0.32
CTSS P25774 2/20 0.32
CTSD P07339 1/20 0.32
ASGR1 P07306 1/20 0.31
FPR3 P25089 1/20 0.31
FPR2 P25090 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA7 P43166 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10260946 0.88 HDAC6 (0.40) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL19865534 0.87 CHRNB2 (0.37) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL1455952 0.85 MVD (0.38) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL18257000 0.85 CA14 (0.42) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL21871862 0.85 GBA1 (0.35) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL25479216 0.85 CA14 (0.42) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL7783463 0.85 HDAC6 (0.38) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL25129557 0.84 MVD (0.37) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL25970378 0.83 CA14 (0.40) GBA1HDAC6CA14HDAC1HDAC2
SCHEMBL17337834 0.82 GBA1 (0.36) GBA1HDAC6CA14HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10682418-B2 Polymer-sunitinib conjugates NEKTAR THERAPEUTICS (US) 2020-06-16 US disclosed
US-20180043028-A1 POLYMER-SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180043028-A1 POLYMER-SUNITINIB CONJUGATES FLT4, TEK, TIE1 GBA1 2931/4885HDAC6 310/4885CA14 1889/4885
US-10682418-B2 Polymer-sunitinib conjugates FLT4, TEK, TIE1 GBA1 2931/4885HDAC6 310/4885CA14 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.